Cot/tpl2 (also known as MAP3K8) has emerged as a new and potentially interesting therapeutic anti-inflammatory target. Here we report the first study of Cot/tpl2 involvement in acute peripheral inflammation in vivo. Six hours following an intraplantar injection of zymosan, Cot/tpl2 -/-mice showed a 47% reduction in myeloperoxidase activity, concomitant with a 46% lower neutrophil recruitment and a 40% decreased luminol-mediated bioluminescence imaging in vivo. Accordingly, Cot/tpl2 deficiency provoked a 25-30% reduction in luminol-mediated bioluminescence and neutrophil recruitment together with a 65% lower macrophage recruitment 4 hours following zymosan-induced peritonitis. Significantly impaired levels of G-CSF and GM-CSF, and of other cytokines such as TNF IL-1 and IL-6, as well as some chemokines such as MCP-1, MIP-1 and KC were detected during the acute zymosaninduced intraplantar inflammatory response in Cot/tpl2 -/-mice. Moreover, Cot/tpl2 deficiency dramatically decreased the production of the hypernociceptive ligand NGF at the inflammatory site during the course of inflammation. Most importantly, Cot/tpl2 deficiency significantly reduced zymosan-induced inflammatory hypernociception in mice, with a most pronounced effect of a 50% decrease in comparison to Wt, at 24 hours following intraplantar injection of zymosan. At this time Cot/tpl2 -/-mice showed significantly reduced NGF, TNF and PGE 2 levels in comparison to Wt littermates. In conclusion, our study demonstrates an important role of Cot/tpl2 in the NGF, G-CSF and GM-CSF production and myeloperoxidase activity in the acute inflammatory response process and its implication in inflammatory hypernociception.
Cot/tpl2 (also known as MAP3K8) has emerged as a new and potentially interesting therapeutic anti-inflammatory target. Here we report the first study of Cot/tpl2 involvement in acute peripheral inflammation in vivo. Six hours following an intraplantar injection of zymosan, Cot/tpl2 -/-mice showed a 47% reduction in myeloperoxidase activity, concomitant with a 46% lower neutrophil recruitment and a 40% decreased luminol-mediated bioluminescence imaging in vivo. Accordingly, Cot/tpl2 deficiency provoked a 25-30% reduction in luminol-mediated bioluminescence and neutrophil recruitment together with a 65% lower macrophage recruitment 4 hours following zymosan-induced peritonitis. Significantly impaired levels of G-CSF and GM-CSF, and of other cytokines such as TNF IL-1 and IL-6, as well as some chemokines such as MCP-1, MIP-1 and KC were detected during the acute zymosaninduced intraplantar inflammatory response in Cot/tpl2 -/-mice. Moreover, Cot/tpl2 deficiency dramatically decreased the production of the hypernociceptive ligand NGF at the inflammatory site during the course of inflammation. Most importantly, Cot/tpl2 deficiency significantly reduced zymosan-induced inflammatory hypernociception in mice, with a most pronounced effect of a 50% decrease in comparison to Wt, at 24 hours following intraplantar injection of zymosan. At this time Cot/tpl2 -/-mice showed significantly reduced NGF, TNF and PGE 2 levels in comparison to Wt littermates. In conclusion, our study demonstrates an important role of Cot/tpl2 in the NGF, G-CSF and GM-CSF production and myeloperoxidase activity in the acute inflammatory response process and its implication in inflammatory hypernociception.
Activation of the pattern recognition receptors, which include TLRs, RIG-I-like receptors, NOD-like receptors and C-type lectin receptors, by pathogen-associated molecular patterns starts a program that culminates in the development of an inflammatory process (reviewed in (1) ). TLRs as well as IL-1Rs, despite their marked differences in their extracellular regions, have a conserved cytoplasmic TIR domain (reviewed in (2) ). Cot/tpl2, also known as MAP3K8, is the sole MAP3K that activates the MKK1/2-Erk1/2 pathway in response to stimulation of the TLR/IL-1 receptor superfamily, as well as in response to the activation of some receptors of the TNF family (3) (4) (5) (6) (7) (8) (9) (10) . However, Cot/tpl2 does not participate in the activation of Erk1/2 by stimulation of the C-type lectin receptor dectin-1 (11) .
In resting cells, Cot/tpl-2 forms a stable and inactive complex with p105 NF-B and ABIN2 (A20-binding inhibitor of NF-B2), among other proteins, to protect Cot/tpl-2 from degradation. Adequate TLR/IL-1R stimulation induces the activation of the IKK complex; active IKK kinase phosphorylates p105 NF-B, triggering its partial degradation to p50 NF-B (12) (13) (14) (15) . Cot/tpl2 is then dissociated from the complex and with an adequate phosphorylation state (16) (17) (18) (19) ) is capable to activate MKK1 and consequently Erk1/2 (6, (20) (21) (22) , prior to being rapidly degraded through the proteasome pathway (6, 20, 23) . Cot/tpl2 is required to process pre-TNFto its mature secreted form in LPS-stimulated macrophages (24). In addition, in different isolated cell types Cot/tpl2 controls the secretion of other cytokines and chemokines such as IL-8, MCP-1, MIP-1, KC and IL-6 (3,10,24-27). Moreover, Cot/tpl2 activation is necessary for the production of PGE 2 in LPSstimulated macrophages (9) . By studying Cot/tpl2 deficient mice, Cot/tpl2 has been demonstrated to participate in LPS-induced septic shock (7) and inflammatory bowel disease in vivo (28). Hence, Cot/tpl2 fulfils a role in innate and adaptive immunity that cannot be substituted for by any other protein.
The MAP kinase Erk1/2, participates in many different biological processes. The precise biological role in which Erk1/2 is involved is given by the nature of the extracellular signal and consequently the MAP3K, such as RAF or Cot/tpl2 that triggers its activation. Cot/tpl2 provides an alternative, independent of other MKK1/2 kinases, mode of MKK1-Erk1/2 activation, thus providing a more specific target for pharmacological manipulation, without fully disturbing the Erk1/2 function. Thus, Cot/tpl2 has emerged as an attractive target to develop new and improved anti-inflammatory drugs (29,30). Indeed, there is now enormous interest in the development of small compounds to specifically block Cot/tpl2 activity to identify new therapeutic anti-inflammatory agents (31-36).
Zymosan has been extensively used as an inducer of acute inflammation in mice hindpaws. Here, we show that Cot/tpl2 mediates zymosan-induced inflammatory processes in vivo, and, as inflammation often results in the development of pain, Cot/tpl2 is involved in the maintenance of inflammatory hypernociception in mice. Furthermore, we also demonstrate that Cot/tpl2 modulates the number of neutrophils recruited to inflammatory foci induced by zymosan injection in vivoas well as the level of cytokines/chemokines, NGF, prostaglandin (PG) E 2 and leukotriene (LT) B 4 production at those sites. (37) . The different samples were triturated in special tubes with matrix Lysing A (MP, Biomedicals) through 3 cycles of 6 sec on ice in the Fastprep-24 apparatus (MP, Biomedicals). The different homogenized extracts were subjected to a 14,000g x 10 min at 4ºC centrifugation and supernatants were frozen at -80ºC until used. COX2 mRNA levels were determined by qRT-PCR analysis using specific COX2 TAQMAN primers (Applied Biosystems). Cot/tpl2 protein expression was determined in homogenized intraplantar extracts as described previously (37) . Intraplantar cells were isolated as described previously with some minor modifications (38, 39) . Briefly, intraplantar tissue corresponding to 6 hindpaws was digested for 1 h at 37ºC in 800 l of RPMI 1640 medium containing 10% FBS, 3 mg/ml collagenase (Sigma) and 1 mg/ml hyaluronidase (Sigma), with constant gentle rocking. The digested fragments were pressed through a 50-m nylon filter (BD) to remove particles. Isolated cells were washed twice in PBS and subjected to flow cytometry analysis using the antibodies described below and according to a previously published method (40) with TrucCOUNT tubes (BD). Control experiments showed that incubation of peritoneal cells with collagenase and hyalorunidase for 1 h at 37ºC did not alter the surface antigen phenotype of the cells (data not shown). Luminol-mediated bioluminescence imaging in vivo and measurement of myeloperoxidase activity in intraplantar extracts-The bioluminescence generated after luminol intraperitoneal injection was measured in the whole animals as described previously (41) . Briefly, after the intraplantar or i.p. zymosan injection, luminol (5 mg/100 µl; Sigma) was i.p. injected and the bioluminescence (BLI) was recorded in an IVIS lumina at the times indicated (XENOGEN). To avoid the absorption of the bioluminescence by the black skin of the C57BL/6J mice, zymosaninduced peritonitis was performed in the C57 albinos [B6(Cg)-Tyr<c-2j>/J C57] Wt and Cot/tpl2 -/-mice. Myeloperoxidase (MPO) activity was measured as described previously (42) with some minor modifications. Briefly, intraplantar tissue was pulverized in liquid N 2 and then homogenized in PBS and subsequently snap-frozen in dry ice and thawed on three consecutive occasions. Debris were removed by a 2,000g x 20 min at 4ºC centrifugation and the supernatant was frozen at -20ºC. Measurement of MPO activity was performed in triplicate using 50 l of intraplantar extracts or 50 l of PBS with 0.5% HTAB, 150 l of PBS, 15 l of 0.22 M Na 2 PO 4 , 20 l 0.034% H 2 O 2 and 20 l of 18 mM TMB (Sigma) diluted in 8% dimethylformamide. After 5 min incubation at 37ºC the reaction was then terminated with H 2 SO 4 (50 μl, 0.18 M), and absorbance measured (450 nm). Protein concentration was determined as described previously (37) .
EXPERIMENTAL PROCEDURES
Western blot of bone marrow-derived macrophage extracts-Bone marrow derived macrophages (BMDM) were cultured as described previously (43) , stimulated with zymosan (10 g/ml) and at the times indicated, the cell supernatants were frozen in liquid nitrogen and the cells (5x10 6 ) were utilized to prepare extracts for analysis in western blots (37) using anti-COX2 (Santa Cruz, Biotechnology) and anti-Erk2 (Santa Cruz, Biotechnology) antibodies. Flow cytometry analysis of cytokines/chemokines and of isolated cellsLavage of the peritoneal cavity was performed with 3 ml of PBS and after a 30 s gentle manual massage, the peritoneal exudate containing fluid and leukocytes was retrieved. After centrifugation, the peritoneal fluid was used to evaluate the concentration of different chemokines and cytokines by FACS analysis. Cells obtained from the peritoneal lavages were washed twice in PBS, counted by two independent investigators blind to the source of the samples, and resuspended in 1 ml of PBS with 0.5% BSA. For phenotype analysis, peritoneal or intraplantar isolated cells (0.3-0.5×10 6 cells/test) were pretreated with CD16/32 (2.4G2, Fc block, Cultek) for 20 min in ice, and they were subsequently stained with antibodies raised against the following proteins at a concentration of 5 μg/ml: F4/80 (rat anti-mouse, eBioscience) for macrophage detection, Ly-6G (rat anti-mouse, Pharmingen) for neutrophil identification or their corresponding isotype controls (Pharmingen). The samples were analysed by flow cytometry after multiple washing and the data were examined using the CXP program. To quantify simultaneously the concentration of TNF, IL-1, IL-6, MIP-1, MIP-1, KC, MCP-1, G-CSF and GM-CSF in plantar tissue extracts, culture supernatants or in peritoneal exudates, CBA Cytometric (BD) kits were utilized. Fluorescence intensities were assayed by flow cytometry in a FACS Canto Cytometer (BD) and they were compared with a standard curve generated for each cytokine to determine the concentration in each sample. The data were analyzed utilizing the FCAP Array TM program (BD). NGF, PGE 2 and LTB 4 measurement-NGF levels were determined in mice hindpaw extracts using the mouse NGF Sandwich ELISA Kit (Millipore), according to the manufacturer's instructions. PGE 2 and LTB 4 were measured in BMDM culture supernatants and in tissue plantar extracts using commercially available PGE 2 and LTB 4 enzyme immunoassay kits (Cayman Chemicals). The analysis was performed by the company blind to the source of the samples.
Measurement of hindpaw swelling and Evans blue extravasation-
The maximal dorsoplantar thickness and medio-lateral width measured proximal to the toes, were determined at different times after zymosan (left hindpaw) or saline (right hindpaw) injection using a digital caliper (Starrett). This instrument has a resolution of 0.05 mm. Evans blue plasma extravasation was studied as described previously (44) . Briefly, Evans blue (50 mg/kg) was injected intravenously into the lateral tail vein and immediately afterwards, zymosan was intraplantar injected into the left hindpaw and PBS into the right hindpaw. After 4 h, the intraplantar tissue was removed, chopped up and incubated in formamide for 24 h at 56°C. The Evans blue extracted was measured spectrophotometrically at 600 nm. Behavioural procedures-Behavioural tests were performed in a low lit and quiet room, always by the same researcher who was blind to the treatment. On the day of the behavioural experiments, the animals were habituated to the apparatus for at least 30 min before beginning the behavioural testing. The animals were placed in plexiglas chambers (12x8x16 cm) with a wire mesh floor and the plantar surface of the hindpaw was stimulated using a hand-held force transducer (electronic anaesthesiometer, IITC Life Science, CA, USA) with a semi-flexible polypropylene probe-tip (0.5 mm 2 diameter). The probe was applied perpendicular to the central area of the paw, gradually increasing the force until the animal withdrew its foot with a clear flinching action. The left and right hindpaws were stimulated alternatively 3 times, at intervals of at least 1 min, and the average score of the 3 readings was taken as the threshold value for paw withdrawal. All mice were tested before any inflammatory procedure in order to establish a baseline level of responsiveness. In the zymosan experiment, the baseline withdrawal threshold was 6.9±0.2g (n=16). The results are presented as the difference in withdrawal thresholds (in grams) before (t=0) and after injection of the inflammatory agents. The behavioural analysis was performed 3, 6, 24 and 48 h after zymosan injection. Statistical analysis-The results are presented as the means ± SEM. The behavioural outcomes were compared by means of a 2-way ANOVA with a Tukey post-hoc test and the rest of the data were analysed with the Students t-test. Values were taken to be statistically significant at p<0.05 (p<0.05 *, p<0.01 **, p<0.001 ***).
RESULTS
Cot/tpl2 modulates zymosan-induced MPO activity in mice hindpaws. Zymosan stimulates both dectin-1 and TLR2/6 receptors. Thus, to ensure a role of Cot/tpl2 in the zymosan intracellular signalling through TLR2/6, we stimulated Wt and Cot/tpl2 -/-BMDM, which express low levels of dectin-1 but high levels of TLR2/6 (45), with zymosan and found no increase in the phosphorylation state of Erk1/2 in Cot/tpl2 -/-BMDM (Fig. S1) . Moreover, we ensured that Cot deficiency does not modify the normal stratified skin epithelium or epidermal-dermal organization in the hindpaws of the mice (Fig. 1A,B) . MPO is one of the principal components of the azurophilic granules in neutrophils and as such, it has been extensively used as a marker of neutrophil infiltration and acute inflammation (46, 47) . Luminol-mediated bioluminescence in vivo has been recently reported to determine the MPO activity at the inflamed site (41) , thus the amount of bioluminescence produced after luminol intraperitoneal injection was determined in vivo 0.5, 6 and 24 h following the injection with zymosan in the plantar region of the Wt and Cot/tpl2 -/-mice left hindpaw. There was a significant decrease in the bioluminescence generated in Cot/tpl2
-/-hindpaws 6 h after the injection of zymosan (Fig. 1C-E) . The bioluminescence observed 24 h later in both Wt and Cot/tpl2 -/-hindpaws had returned to almost basal levels (Fig. 1C) . In concordance with these data, Cot/tpl2 -/-hindpaw extracts 6 h following zymosan injection showed a 47% decreased MPO specific activity in comparison to zymosan-injected Wt hindpaws extracts (Fig. 1F ). Since this decrease in MPO activity in Cot/tpl2 -/-hindpaws could indicate a decrease in the number of infiltrated neutrophils, the number of inflammatory cells was determined in zymosan-injected Wt and Cot/tpl2 -/-hindpaws. To this end, Wt and Cot/tpl2 -/-intraplantar tissues 6 h following intraplantar injection of zymosan were subjected to collagenase and hyaluronidase digestion and isolated cells were subsequently subjected to flow cytometry analysis (Fig. S2) . Cot/tpl2 -/-inflamed intraplantar tissue showed 46% less neutrophils (Ly-6G + F4/80 -) than their Wt counterpart (Fig. 1G) (Fig. 2B,C) . Nevertheless, when the reduction in the total number of cells recruited from the peritoneum of Cot/tpl2 -/-mice was taken into account, Cot/tpl2 deficiency not only provoked a decrease of about 65% in the number of macrophages recruited but also, a decrease of about 25% in the total number of neutrophils recruited (Fig. 2D) . Accordingly, Cot/tpl2 -/-mice showed about 30% less luminol-mediated bioluminescence in vivo 4 h after the i.p. injection of zymosan (Fig. 2E,  S3 ). Recent evidences point to MPO to control the inflammation by activating the neutrophils through its association with integrin CD11b/CD18, emerging MPO as a mayor player controlling inflammation (48) (49) (50) (51) . Nevertheless, it should be noted that no significant differences were observed in the expression of CD11b in Wt and Cot/tpl2 -/-macrophages or neutrophils (Fig. S4) .
Modulation of chemokines and cytokines production by Cot/tpl2 deficiency in vivo. The release of the chemokines MIP-1, MIP-1, MCP-1 and KC at the acute inflammatory focus is responsible for the recruitment of inflammatory cells (52, 53) . Thus, we analyzed the role of Cot/tpl2 in the secretion of these chemokines induced by zymosan in the intraplantar tissue. MIP-1concentration decreased significantly within the first 2 h of zymosan injection in the intraplantar tissue of Cot/tpl2 -/-mice (Fig. 3) . By contrast, both Wt and Cot/tpl2 -/-hindpaws had similar levels of MIP-1during the progression of inflammation (Fig. 3) . A significant decrease in MCP-1 levels was observed 5 h after zymosan injection in the hindpaws of Cot/tpl2 -/-mice in comparison to zymosan-injected Wt hindpaws, whilst in zymosan-injected Cot/tpl2 -/-intraplantar tissue KC levels were reduced by 25% with respect to the Wt intraplantar tissue 2 h after the initiation of inflammation (Fig.  3) .
Taking into account the established role of GM-CSF and G-CSF in recruiting and also maintaining macrophages and neutrophils active at the inflammatory site (54-56), we also studied the possible role of Cot/tpl2 in modulating the levels of these mediators at the inflammatory site. In the hindpaws of Wt mice, maximal levels of GM-CSF were detected 5 h after zymosan injection and at this time, the GM-CSF levels in Cot/tpl2 -/-were decreased significantly. Similarly, a decrease in G-CSF in the hindpaws of Cot/tpl2 deficient mice was detected 2 h after zymosan injection.
TNF, IL-1 and IL-6 are the main proinflammatory cytokines that activate the nociceptive terminals that innervate the inflamed tissues (52, 53, 57) . Thus, we also decided to evaluate their levels during the course of zymosan-induced hindpaw inflammation. In zymosan-injected hindpaws of Cot/tpl2 -/-mice there was a tendency to produce lower TNF, with a significant reduction of about 20% 24 h following zymosan injection in comparison to Wt littermates (Fig. 3) . A significant 30% decrease in IL-1 in zymosan-injected hindpaws of Cot/tpl2 -/-mice was evident at 5 h. Furthermore, Cot/tpl2 deficiency also provoked lower levels of IL-6 within the first 2 h after intraplantar zymosan-induced inflammation (Fig. 3) .
NGF, PGE 2 and LTB 4 production in zymosan-injected intraplantar tissue of Wt and Cot/tpl2
-/-mice. NGF and PGE 2 are key participants in the pain sensitization at the inflamed site (52, 53, 58) . The rapid increase of NGF at the inflammatory site is dependent, among other signals, on the concentration of IL-1 and TNF (58) (59) (60) . The quantification of NGF levels during the progression of inflammation in zymosan-injected Wt and Cot/tpl2 -/-hindpaws showed that Cot/tpl2 is a master regulator of the production of this pronociceptive factor (Fig. 4A) .
On the basis of Cot/tpl2 capacity to trigger PGE 2 as well as TNF production in LPSstimulated BMDM, Cot/tpl2 has been proposed as a new interesting antiinflammatory target (29,30). Indeed, COX2 expression is impaired in Cot/tpl2 deficient BMDM within the first 10 h of LPS stimulation (9) . Likewise, COX2 protein and PGE 2 production were also impaired in zymosan-stimulated Cot/tpl2 -/-macrophages 8 h after zymosan stimulation. However, after 24 h only a minor decrease in PGE 2 levels was evident in Cot/tpl2 -/-BMDM and there were no significant differences in the levels of COX2 in Cot/tpl2 -/-in comparison to Wt littermates (Fig. 4B ). More importantly, the levels of PGE 2 in the extracts of zymosaninjected intraplantar tissues from both Wt and Cot/tpl2 -/-mice unexpectedly showed that Cot deficiency increased the concentration of PGE 2 2-fold 5 h after the intraplantar injection of zymosan; however 24 h following zymosan injection a 25% decrease was observed (Fig.  4C) . These data correlated with the levels of COX2 mRNA detected in the zymosaninjected intraplantar tissue of Cot/tpl2 -/-mice (Fig. 4D) . LTB 4 is involved in the expression of PGE 2 in zymosan-induced joint hypernociception (61) and thus, LTB 4 was measured at different times after zymosan injection in Wt and Cot/tpl2 -/-hindpaws. Cot/tpl2 deficiency was associated with an increase in LTB 4 levels at 5 h, although there was a significant decrease 24 h later (Fig. 4E) . LTB 4 could not be detected in either zymosanactivated Wt or Cot/tpl2 -/-BMDM at any of the different times (0, 1.5, 3, 8 , and 24 h) tested (data not shown).
Induction of oedema formation in zymosaninjected hindpaws of Wt and Cot/tpl2
-/-mice. The formation of oedema is a sign of inflammation and there was a significantly smaller increase in both medio-lateral width and dorso-plantar thickness in the zymosaninjected hindpaws of Cot/tpl2 -/-mice than in Wt 3 h after intraplantar zymosan injection (Fig.  5A,B) . Accordingly, plasma extravasation as measured by Evans blue outflow, revealed significantly less extravasation in the paws of Cot/tpl2 -/-mice 4 h after the intraplantar injection of zymosan (Fig 5C) . Nevertheless, similar levels of swelling were observed between the hindpaws of Wt and Cot/tpl2
-/-mice 6 h and 24 h after the induction of inflammation.
Cot/tpl2 is involved in inflammatory hypernociception in mice. Finally, we evaluated how the aforementioned modulation of cytokine/chemokine, NGF and PGE 2 production at the inflammatory site observed in vivo as a consequence of the deficiency of Cot/tpl2, affects the whole process of acute inflammation.
Inflammatory pain is characterized by hypernociception whereby the intensity of the sensitisation to a painful stimulus is preceded by and is directly dependent on the recruitment of inflammatory cells and the release of inflammatory cytokines and pronociceptive ligands (52, 53, 57) . Thus, to evaluate the importance of Cot/tpl2 in inflammation in vivo, we quantified inflammatory hypernociception in the hindpaws of Wt and Cot/tpl2 -/-mice injected intraplantarly with zymosan. Overall, there was a time-dependent reduction in mechanical hypernociception in Cot/tpl2 -/-mice compared with Wt over a 48 h time-course, with the most striking differences evident at 24 h post injection (Fig. 6) . Furthermore, to evaluate the role of Cot/tpl2 in peripheral acute inflammation with a ligand that actives a TLR (TLR4), but not other pattern recognition receptors such as dectin-1, we also studied the role of Cot/tpl2 inflammatory hypernociception by injecting LPS into the hindpaws of the Wt and Cot/tpl-2 -/-mice, detecting again a significant decrease in LPSinduced hypernociception in Cot/tpl2 deficient mice (Fig. S5A,B) .
DISCUSSION
Cot/tpl2 controls Erk1/2 activation by TLR ligands, IL-1 and TNF (3-8,10,62) and its inhibition does not affect the activation of the Erk1/2 pathway by other MAP3Ks. On the basis of its capacity to trigger PGE 2 and TNF production, Cot/tpl2 has emerged as an attractive target to develop new and improved anti-inflammatory drugs (reviewed in (29,30) ). In this article we have studied the role of Cot/tpl2 in peripheral inflammation in vivo, demonstrating a role of Cot/tpl2 in inflammatory hypernociception and providing evidence of deficient neutrophil recruitment. MPO, one of the principal components of the azurophilic granules in neutrophils, has also emerged as a major factor controlling the acute inflammatory process (48) (49) (50) (51) and our data demonstrate that Cot/tpl2 deficient mice show decreased luminol-mediated bioluminescence determined in vivo in two different zymosaninduced inflammation models and decreased MPO activity measured in vitro in intraplantar extracts of Cot/tpl2 -/-mice hindpaws injected with zymosan. This loss of MPO activity is in accordance with the lower number of recruited neutrophils at the inflamed site in Cot/tpl2 -/-mice. The impaired recruitment of cells induced by Cot/tpl2 deficiency is consistent with the decreased levels of different chemotactic factors (53) (54) (55) (56) 63, 64) such as MIP-1KC, G-CSF and/or GM-CSF detected within the first 5 h of inflammation in Cot/tpl2 -/-mice. Cot/tpl2 has an established essential role in the secretion of MCP-1, MIP-1, KC and IL-6 in several isolated cell types mainly following LPS stimulation but also, when stimulated with IL-1 (3,10,24-27). However, our data here indicate that the contribution of Cot/tpl2 on the expression of a specific cytokine or chemokine in vivo is not as straightforward as detected in single isolated cell types. It is important to note that Cot/tpl2 -/-BMDM stimulated with zymosan show similar KC and MCP-1 secretion levels as previously reported for LPS-stimulated BMDM (data not shown). Indeed, and as expected in a dynamic process, our data indicate that the role of Cot/tpl2 on the production of certain inflammatory mediators varies during the inflammatory response. This hypothesis is reinforced by the fact that in the modulation of the hypernociceptive response the main striking difference is observed at 24 h, but differences in paw-swelling by Cot/tpl2 deficiency are only observed at 3 h following the zymosaninduced inflammation response. Nevertheless, here we demonstrate that the expression levels of GM-CSF and G-CSF, with an active role in recruiting and maintaining active macrophages and neutrophils at the inflammatory focus (54) (55) (56) , are modulated by Cot/tpl2.
Cot/tpl2 has been proposed to be essential for the TNF secretion in response to LPS stimulation.
The prior intravenously administration of a Cot/tpl2 inhibitor in rats reduced TNF plasma levels by 85% at 90 min following LPS administration (35) . Besides, Cot/tpl2 -/-mice hardly produce any TNF within the first 30 and 60 min after i.p. injection of LPS/D-Galactosamine (7). Besides, Cot/tpl2 -/-mice show a 50% decrease in TNF levels in the peritoneum after 2 or 3 h of zymosan i.p. injection (data not shown and (11)). In contrast, in zymosan-induced intraplantar inflammation Cot/tpl2 hardly regulates TNF production within the first 5 h following zymosan injection, but a significant TNF decrease by Cot/tpl2 deficiency is observed 24 h after the induction of inflammation.
Cot/tpl2 controls the production of PGE 2 in LPS stimulated Cot/tpl2 deficient BMDM (62) , as well as in IL-1 stimulated rheumatoid arthritis fibroblast-like synoviocytes (27). The expression of COX2 is impaired in zymosan stimulated Cot/tpl2 deficient BMDM within the first 8 h of stimulation, as is PGE 2 production, although these data do not correlate with that observed in vivo. In this context, it is again clear that the tissue microenvironment is more complex than isolated cell systems. LTB 4 plays an important role in inflammatory hypernociception. It has been shown to mediate the secretion of PGE 2 in zymosan-induced inflammation in vivo (61) and zymosan induces LTB 4 in mast cells (65) . Thus, considering the correlation between the levels of PGE 2 and LTB 4 during the course of hindpaw inflammation, it remains possible that PGE 2 levels which are increased in 5 h zymosan-injected Cot/tpl2 -/-hindpaws, but decreased 24 h after zymosan injection are LTB 4 mediated.
Inflammatory hypernociception is directly dependent on the production of nociceptive mediators generated at the inflamed site (53, 66, 67) . PGE 2 , TNF, NGF, IL-1 and IL-6 provoke the activation of nociceptive terminals that innervate the inflamed tissues (52, 53, 58) . Our data show that Cot/tpl2 controls the production of NGF during the course of the zymosan-induced inflammation. Decreased levels of IL-1 and IL-6 within the first 5 h after the intraplantar injection of zymosan in Cot/tpl2 -/-mice were also observed. At this time-point, however, the Cot/tpl2 -/-mice reflected a reduction of only about 15% in the hypernociceptive behaviour in comparison to Wt littermates. In this context, it should be noted that at this time increased levels of PGE 2 in Cot/tpl2 -/-zymosan-injected hindpaws were detected. Nevertheless, 24 h following intraplantar injection of zymosan, Cot/tpl2 -/-mice showed a 50% reduction in the hypernociceptive behaviour, together with reduced levels of NGF, TNF and PGE 2 .
In conclusion, our data show that Cot/tpl2 regulates NGF and LTB 4 production, the levels of GM-CSF and G-CSF, and MPO activity along inflammatory response affecting the zymosan-induced acute inflammatory process and the resulting hypernociception. 
